ESOMEPRAZOLE
Acid suppression, started before endoscopy
Strength40 mg
Forminjection
80 mg by intravenous bolus infusion over 30 minutes, then 8 mg per hour by continuous infusion. Where a pump is not available the article's alternative is intermittent dosing of 40 mg two to four times daily. x 72 hours of high-dose therapy, then twice-daily oral acid suppression for 14 days, then once daily to complete ulcer treatment
The 80 mg bolus and 8 mg per hour regimen is an adult one and neither document extends it to children. The formulary's separate paediatric intravenous entry is for gastric antisecretory treatment when the oral route is not possible - 0.5 mg/kg once daily from 1 month to under 1 year, 10 mg once daily from 1 to 17 years under 55 kg, 20 mg at 55 kg and over, each infused over 10 to 30 minutes for up to 10 days. Melaena in a child is an emergency paediatric referral.
Egyptian National Drug Formulary - GIT 2024 (esomeprazole monograph, p73), which for prevention of rebleeding after therapeutic endoscopy for acute bleeding gastric or duodenal ulcer gives an 80 mg intravenous bolus infusion over 30 minutes followed by a continuous infusion of 8 mg per hour over 3 days, then oral acid suppression. The same two figures appear in the card's own upper gastrointestinal bleeding article, which puts them before endoscopy as well.
The article states that patients with significant bleeding should have an 80 mg proton pump inhibitor bolus followed by 8 mg per hour, or intermittent 40 mg two to four times daily, and reports that giving a high-dose inhibitor before endoscopy reduced high-risk ulcer features and the need for endoscopic therapy in a randomised trial. It names the class rather than a drug; esomeprazole is the drug the Egyptian formulary carries at exactly these figures, and seven intravenous products are marketed here.
- The transfer comes first. Acid suppression is started while the ambulance is arranged, never instead of it - black tarry stool means upper gastrointestinal bleeding until proven otherwise.
- Two documents place the same regimen at different moments and both are recorded: the formulary gives 80 mg then 8 mg per hour for preventing rebleeding after therapeutic endoscopy, while the article gives the identical figures before endoscopy. The evidence the article cites for the pre-endoscopy use showed fewer high-risk ulcer features and less endoscopic therapy, with no difference in transfusion, rebleeding or 30-day mortality.
- Ask about anticoagulants before anything else. The article's threshold for holding the drug and giving a reversal agent is a life-threatening bleed - shock, severe hypotension needing vasopressors, a haemoglobin fall of more than 5 g/dL, or 5 or more units transfused - and it prefers prothrombin complex concentrate to fresh frozen plasma on a vitamin K antagonist.
- Iron and bismuth blacken the stool without any bleeding. Confirm with a rectal examination rather than a history alone.
- Contraindicated in hypersensitivity to any substituted benzimidazole proton pump inhibitor.
| Egyptian brand | Manufacturer | Indicative price |
|---|---|---|
| MERAZODEL 40 MG POWDER FOR I.V. INF. VIAL | DELTA PHARMA | 31.20 EGP |
| ESOMEPEX 40 MG POWDER FOR I.V. INF. VIAL | INTERNATIONAL DRUG AGENCY (IDI) > NOVELL PHARMA | 41.50 EGP |
| ZOMEGIPRAL 40MG POWDER FOR I.V. INF. VIAL | GLOBAL PHARMACEUTICAL INDUSTRIES | 48.00 EGP |
| MEGAPRAZOLE 40 MG POWDER FOR I.V. INF. VIAL | CHEMIPHARM | 53.00 EGP |
| ESMORAP 40 MG POWDER FOR I.V. INF. VIAL | EL NILE. > AUG PHARMA | 86.00 EGP |
| NEXIUM 40 MG POWDER FOR I.V. INF. VIAL | ASTRA ZENECA | 100.00 EGP |
| ESOMEPRAZOLE-EVA 40MG 3 POWDER FOR I.V. INF. VIAL | EVA PHARMA | 204.00 EGP |